Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Vi...( SAN DIEGO April 23 /- Vical Incor...),Health

SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the release to television news stations nationwide of an independently produced video report featuring metastatic melanoma patients treated with the company's Allovectin-7(R) immunotherapeutic product candidate. The report is expected to be used broadly by stations in cities with clinical sites participating in Vical's Phase 3 Allovectin-7(R) trial, and in other cities by stations promoting melanoma awareness in May, which is National Melanoma/Skin Cancer Detection and Prevention Month. The two-minute video report was produced by MAX World News and is available by satellite feed to subscribing stations.

The video report features interviews with an oncologist and two of his patients who participated in earlier trials of Allovectin-7(R). Both patients had been treated previously with approved therapies and had refractory metastatic melanoma before receiving Allovectin-7(R). One patient had several metastatic tumors, including three in the liver, and had been advised that he should expect to live only three months. The other patient had a single metastatic tumor in a lymph node. Following treatment with Allovectin-7(R), both of these patients had complete remissions and have now been cancer-free for six and eight years, respectively.

About Allovectin-7(R)

Allovectin-7(R) is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and .2 microglobulin, which together form a Class I Major Histocompatibility Complex, or MHC-I antigen. Injection of Allovectin-7(R) directly into tumors is designed to stimulate an immune response against both local and distant metastatic tumors. Vical conducted a large Phase 2 trial eval
'/>"/>